AXOTAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AXOTAL (AXOTAL).
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
| Metabolism | Butalbital is metabolized primarily by CYP2C19; acetaminophen is metabolized mainly via glucuronidation by UGT1A1 and UGT1A6, sulfation by SULT1A1, and minor oxidation by CYP2E1. |
| Excretion | Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%). |
| Half-life | Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98-99% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg, indicating distribution mainly in extracellular fluid and limited tissue penetration. |
| Bioavailability | Oral: 85-95%; intramuscular: 90-100%; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intramuscular: 15-30 minutes; intravenous: 5-10 minutes. |
| Duration of Action | 4-6 hours for oral and intramuscular routes; 2-4 hours for intravenous; analgesic effect may persist up to 8 hours in some patients. |
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; contraindicated in severe renal impairment (CrCl <30 mL/min). Use with caution in mild-moderate impairment due to acetaminophen and butalbital accumulation. |
| Liver impairment | Contraindicated in Child-Pugh Class C (severe hepatic impairment). In Child-Pugh A or B, reduce dose or extend interval; maximum acetaminophen 2000 mg/day, avoid butalbital if possible. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-18: same as adult dose (1-2 tablets) but limit to 4 tablets per day and monitor for sedation. |
| Geriatric use | Start at lower dose (1 tablet every 6 hours) due to increased sensitivity to butalbital (cNS depression, falls) and acetaminophen hepatotoxicity risk; limit to 4 tablets per day, avoid in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AXOTAL (AXOTAL).
| Breastfeeding | Lithium is excreted into human milk (M/P ratio 0.3-0.8). Breastfeeding is not recommended due to risk of neonatal toxicity (hypotonia, hypothermia, cyanosis, ECG changes). Monitor infant serum levels if breastfeeding is continued. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second and third trimesters: Increased risk of fetal/neonatal toxicity including cardiac arrhythmias, hypoglycemia, polyhydramnios, preterm birth, and neonatal goiter. Avoid if possible; weigh risks vs. benefits. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is usually associated with doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
| Serious Effects |
Hypersensitivity to barbiturates or acetaminophen; porphyria; severe hepatic impairment; respiratory depression; history of substance abuse.
| Precautions | Hepatotoxicity with acetaminophen overdose; risk of rhabdomyolysis, angioedema, Stevens-Johnson syndrome; butalbital dependence and withdrawal; CNS depression; impairment of mental or physical abilities; avoid concurrent alcohol use. |
| Food/Dietary | Avoid alcohol intake; concurrent use increases risk of acetaminophen hepatotoxicity. Grapefruit juice may increase caffeine levels; limit consumption. High-fat meals may delay absorption of butalbital. Maintain adequate hydration; caffeine has mild diuretic effect. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum lithium levels (target 0.6-1.0 mEq/L, lower in pregnancy), renal function (serum creatinine, eGFR), electrolytes, and thyroid function. Fetal monitoring: Serial ultrasound for fetal anatomy (echocardiography for Ebstein anomaly) and growth. Neonatal monitoring: ECG, glucose, thyroid function, and hydration. |
| Fertility Effects | No established adverse effects on female or male fertility. In females, mood stabilization may improve fertility by restoring regularity. Lithium does not impair spermatogenesis or ovarian function in therapeutic doses. |
| Clinical Pearls | AXOTAL (butalbital/acetaminophen/caffeine) is a combination analgesic for tension-type headaches. Butalbital is a barbiturate with addiction potential; limit use to less than 2 days per week to avoid medication overuse headache (MOH). Acetaminophen hepatic toxicity risk increases with chronic alcohol use or pre-existing liver disease. Caffeine may cause withdrawal headaches upon abrupt cessation. |
| Patient Advice | Do not exceed 4 tablets per day to avoid acetaminophen overdose (max 4000 mg/day). · Avoid alcohol while taking this medication due to risk of liver damage. · This drug can be habit-forming; use only as prescribed for headache attacks, not for prophylaxis. · May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react. · Discontinue and seek medical help if you experience signs of liver injury (jaundice, dark urine) or allergic reaction (rash, swelling). · Caffeine content may interfere with sleep or exacerbate anxiety; limit other caffeine sources. |